4th Circuit Upholds Block on West Virginia’s 340B Law

Why It Matters

The split threatens uniform national application of 340B rules, influencing drug pricing, hospital margins, and could prompt Supreme Court review.

Key Takeaways

• 4th Circuit blocks West Virginia's 340B contract pharmacy law
• Decision opposes 5th and 8th Circuits' supportive rulings
• PhRMA and manufacturers sued, seeking preemption relief
• AHA supports West Virginia, urges full circuit rehearing
• Split may trigger national legal battle over 340B discounts

Pulse Analysis

The federal 340B Drug Pricing Program allows eligible hospitals and clinics to purchase outpatient medicines at steep discounts, a mechanism intended to stretch scarce resources for underserved patients. In recent years, several states have tried to extend those savings to drugs dispensed through contract pharmacies, prompting legislation such as West Virginia’s Senate Bill 325. The bill required manufacturers to honor 340B discounts on all prescriptions filled by contract pharmacies, a move that drug makers argued overstepped federal authority. On March 31, the Fourth Circuit affirmed a district court injunction that halts enforcement of the statute.

The ruling creates a stark circuit split, contrasting with decisions from the Fifth and Eighth Circuits that upheld similar statutes in Louisiana and Arkansas. Those courts concluded that state‑mandated 340B discounts do not conflict with federal law, while the Fourth Circuit found the West Virginia measure likely preempted. Pharmaceutical trade group PhRMA and dozens of manufacturers argue the statutes force them to discount drugs beyond the scope of the federal program, inflating compliance costs and eroding pricing predictability. Hospitals relying on contract pharmacies fear reduced access to discounted medicines if the injunction is lifted.

Legal experts anticipate that the split will soon reach the Supreme Court, where the core question is whether states can impose additional 340B obligations without congressional authorization. A decision favoring manufacturers could curtail the growth of contract pharmacy networks, pressuring safety‑net providers to renegotiate pricing or limit services. Conversely, a ruling upholding state laws would reinforce a broader interpretation of 340B, potentially expanding discount availability but also increasing manufacturers’ exposure to litigation and compliance risk. Stakeholders are closely monitoring the case as it could reshape the economics of drug pricing nationwide.